Impact of Tachycardia on Outcome After Subarachnoid Hemorrhage (SAH)

This study is enrolling participants by invitation only.
Sponsor:
Collaborator:
Baxter Healthcare Corporation
Information provided by (Responsible Party):
Stephan A. Mayer, Columbia University
ClinicalTrials.gov Identifier:
NCT01585311
First received: April 24, 2012
Last updated: NA
Last verified: April 2012
History: No changes posted

April 24, 2012
April 24, 2012
April 2012
January 2013   (final data collection date for primary outcome measure)
modified Rankin Scale (mRS) score [ Time Frame: Three months ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Major Adverse Cardiovascular events (MACE) [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  1. pulmonary edema,
  2. severe hypertension or
  3. hypotension requiring IV infusion therapy,
  4. myocardial infarction, and
  5. serious cardiac arrhythmias including sudden cardiac arrest.
  6. length of ICU and hospital stay for patients with and without uncontrolled tachycardia
Same as current
Not Provided
Not Provided
 
Impact of Tachycardia on Outcome After Subarachnoid Hemorrhage (SAH)
Impact of Prolonged Tachycardia on Cardiovascular Morbidity and Outcome After Subarachnoid Hemorrhage (SAH)

The purpose of this retrospective study is to test the hypothesis that uncontrolled tachycardia serves as a risk factor for adverse cardiovascular events and poor outcome after Subarachnoid Hemorrhage (SAH).

The design of the current study will be to conduct a retrospective analysis of prolonged heart rate and uncontrolled tachycardia using patients enrolled in the investigators prospective observational cohort study since the electronic medical record systems have been implemented. The investigators know that there have been periods when these electronic systems have failed, resulting in lost data. The investigators anticipate retrospective collection of hourly heart rate for approximately 400 SAH patients that will have ICU data and 3 month modified Rankin documented in our Subarachnoid Hemorrhage Outcomes Project (SHOP) database. The investigators will determine what percent of them have prolonged elevated heart rate and tachycardia. Prolonged heart rate and uncontrolled tachycardia has been defined as a heart rate greater than 95 for greater than 12 hours in one 24 hour period of their ICU stay. The investigators will conduct a ROC curve analysis to determine the appropriate heart rate and duration thresholds that are most predictive of poor prognosis after SAH. Patients be will stratified based on several criteria including admission coma score, early (SAH day 0 to 3) or late (SAH day >=4) ICU admission, presence of intraventricular hemorrhage on admission CT, history of beta-blocker usage, age, and gender.

Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Patients admitted to the Columbia Neurocritical Care Unit with a diagnosis of subarachnoid hemorrhage established by computed tomography (CT scan) or xanthochromia of the cerebrospinal fluid if the CT is negative.

  • Subarachnoid Hemorrhage (SAH)
  • Tachycardia
Not Provided
Subarachnoid Hemorrhage patients
SAH patients with hourly eMR values of Heart Rate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Enrolling by invitation
400
April 2013
January 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age >=18 years
  • Diagnosis of subarachnoid hemorrhage established by computed tomography (CT scan) or xanthochromia of the cerebrospinal fluid if the CT is negative
  • Written informed consent from either the patient or a family member
  • Admitted to the NICU for at least 12 hours

Exclusion Criteria:

  • Age < 18yrs
  • traumatic SAH
  • SAH due to a rupture of an arteriovenous malformation, neoplasm vasculitis or other secondary causes
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01585311
AAAA5384
No
Stephan A. Mayer, Columbia University
Columbia University
Baxter Healthcare Corporation
Principal Investigator: Stephan A Mayer, MD Columbia University
Study Director: J. Michael Schmidt, PhD Columbia University
Columbia University
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP